CURRICULUM VITAE

UPDATED 23-JUL-08

# Diponkar Banerjee
# MBChB, FRCPC (Anatomic Pathology), PhD (Immunology)
# Clinical Professor, Pathology and Laboratory Medicine
# University of British Columbia
# Executive Medical Director, Provincial Health Services Authority Laboratories, Vancouver, BC.

## OBJECTIVE

**To transform clinical laboratory services in order to create a new benchmark for top quality advanced diagnostic laboratories; promoting excellence in patient-focused advanced diagnostics, research and development, continuing healthcare provider education, and innovative and cost-effective management of healthcare resources for the residents of Canada and beyond, using LEAN/Six-Sigma/outreach management tools. Promoting Theranostics for personalised therapy, predictive sciences and novel risk stratification in screening programs.**

## EXPERIENCE

### AS AN ADMINISTRATOR

27 years in senior administrative roles

21 years as the medical director of clinical laboratories in academic teaching hospitals in Ontario and British Columbia

**Current: Executive Medical Director, PHSA Laboratories, Provincial Health Services Authority; Provincial Program Leader, Cancer Pathology, British Columbia Cancer Agency**

**Previous Positions held:**

October 2006-April 2008
Interim Executive Medical Director, PHSA Laboratories, Provincial Health Services Authority; Provincial Program Leader, Cancer Pathology, British Columbia Cancer Agency

**2000-2006**
Medical Director of Pathology and Laboratory Medicine, Vancouver Cancer Centre
**2000-2002**
Canadian Reference Centre for Cancer Pathology. Western Division, Director.
**1999-2000**
Interim Haematopathologist-in-Chief, University Health Network, Toronto
**1999-2000**
Project Leader, Clinical Research Program in Oncologic Molecular Microimaging (0MM), Princess Margaret Hospital/Ontario Cancer institute, University Health Network, Toronto
**1997- 2000**
Medical Director. Immunology and Immunopathology, Dept. of Laboratory Medicine and Pathobiology, University Health Network, Toronto
**1995-1999**
Canadian Reference Centre for Cancer Pathology. Eastern Division, Director.
**1994-1998**
Head. Division of Oncologic Pathology, Department of Pathology, University of Toronto.

CURRICULUM VITAE

UPDATED 23-JUL-08

| | |
|---|---|
| | **1991-1997**<br>Chief of Oncologic Pathology and Medical Director of Laboratories, Princess Margaret Hospital/Ontario Cancer Institute, Toronto<br><br>**1987-1991**<br>Chairman, Cell Biology Division, Lawson Research Institute.<br>**1987-1991**<br>Chief of Pathology, St. Joseph's Health Centre, London, Ontario.<br>**1979-1987**<br>Director, Immunopathology Laboratory, University Hospital, London, Ontario. |
| **AS AN EDUCATOR**<br><br>30 Years Experience | **July 2000- present:**<br>**Clinical Professor, Department of Pathology and Laboratory Medicine, University of British Columbia**<br>**2001- present:**<br>Site Director, CIHR Strategic Training Program for Clinician Scientists in Oncologic Molecular Pathology<br>**1997-2000**<br>Professor, Department of Laboratory Medicine & Pathobiology, University of Toronto.<br>**July 91-June 97**<br>Professor, Department of Pathology, University of Toronto.<br>**July 83-June 91.**<br>Associate Professor, Department of Pathology, University of Western Ontario.<br>**July 78-June 83.**<br>Assistant Professor, Department of Pathology, University of Western Ontario.<br>**1986-1987**<br>Director, General Pathology Residency Training Program, University of Western Ontario.<br>**1981-1984**<br>Director, Laboratory Medicine Residency Training Program, University of Western Ontario.<br>**1981-1884**<br>Director. Anatomical Pathology Residency Training Program. University of Western Ontario.<br>**1978-1981**<br>Director, Medical Technologists Training Program, London, Ontario.<br><br>**Post-Doctoral Fellows Trained:**<br>Dr. Licia Scremin. University of Western Ontario. 1989-90.<br>Dr. Ya Ping Guo, University of Toronto 1996-98<br>Dr. J. Chiang, University of Toronto 1998<br>Dr. W. Shi University of Toronto 1998-2000<br>Dr. Minglong Zhou 2003 -<br>Dr. Faisal M. Fadl El Mola 2004 –<br>**GRADUATE STUDENT SUPERVISION:**<br>Marien Zanyk — PhD in Pathology. — 1986-90<br>Henry LaPointe — PhD in Pathology. — 1986-90<br>W. David Colby — PhD in Pathology. — 1985-86<br>Joanne Baril — MSc in Pathology. — 1984-67<br>Nee Nartey — MSc in Pathology. — 1985-87<br>**Thesis Examinations:** |

CURRICULUM VITAE

UPDATED 23-JUL-08

| | |
|---|---|
| | Ph.D. External Examiner - Amila Orucevic, University of Western Ontario. Department of Anatomy. June 5.1996.<br>Ph.D. Extra-departmental Examiner- Hyewon Lee-Han, M.Sc., August 19,1992, topic-Diet, Histological and Radiological Indicators of Breast Cancer Risk in Women with Benign Breast Biopsies": supervisor Dr. N. Boyd.<br>I have acted as an extra-departmental examiner for the Department of Immunology and Microbiology for 6 graduate students (for PhD), 1980, 1981, 1982,1984,1986,1990. and 1 for the Department of Anatomy in 1988, University of Western Ontario. (Total: 7).<br>I have been an examiner for 4 MSc students in Pathology, 1979, 1981, 1983 and 1987, and 1 for Anatomy in 1990. |
| **AS A RESEARCHER**<br>33 years experience<br>173 publications, abstracts and book chapters<br>41 invited lectures<br>$27.2 million in cumulative research funding as principal investigator or co investigator | **Invited Lectures:**<br>1. Bridging Genomics and Therapy – Creating a Theranostics Paradigm - CADTH Session 13 – Innovation and Emerging Technologies April 29 2008, Edmonton.<br>2. The Future Impact of Genomics and Proteomics on the Practice of Pathology. 16th International Congress of Cytology, Vancouver, May 16, 2007.<br>3. Genomics and Proteomics: Applications and Future Directions. Japanese Society for Clinical Cytology, Yokohama, Japan, April 2006.<br>4. What's New in Hodgkin Lymphoma? – Canadian Association of Pathologists Annual Meeting, St. Johns NFL. July 2006<br>5. What's New in Hodgkin Lymphoma? – American Society for Clinical Pathology Annual Meeting Las Vegas. October 2006<br>6. Bridging Genomics and Pathology – Creating a Theranostics Paradigm- Invited Lecture Children's and Women's Health Centre of British Columbia Department of Pathology and Laboratory Medicine, 18 April, 2006.<br>7. Role of Pathology in Predictive and Personalized Medicine: Health and Economic Outcomes. American Society of Clinical Pathology. October 9th, 2005, Seattle, Washington.<br>8. Best Practice Standards for EGFR Testing in Colorectal Cancer in Canada; Canadian Association of Pathologists Annual Meeting, Victoria, BC, June 2005<br>9. Novel Monoclonal Antibodies against Hodgkin Lymphoma; 4th Pan Arab Cancer Congress: Recent Advances in Cancer Management in the New Millennium; March 28-31, 2002; The Ritz Carlton Hotel, Doha, Qatar.<br>10. Evolving Issues in Oncology: Taking AIM at the Future (Lectured on the use of Tumour Tissue Banks in Genomic and Proteomic Research); |

Victoria BC. Oct. 27-28, 2001

11. Becton Dickinson Canada Flow Cytometry Seminar, January 23, 1997, Toronto. "Grading of Non-Hodgkin's Lymphoma Using S-Phase Fraction.

12. C.S.L.T., Ottawa, June 19,1995. "Uses of Flow Cytometry in Pathology".
13. Lectures to AACR and OCTRF Coding Workshop, 1995.

14. Spectrum: A Breast cancer Symposium, Toronto, September 30-October 1,1994, "Host-Tumour Interactions: The Role of the Immune System".

15. St. Joseph's Institute of Laboratory Medicine Symposium, London, Ontario, April 29,1993, "Some Newly Described Varieties of Non-Hodgkin's Lymphoma, and Some Old Ones with New Names".

16. Academy of Medicine, Toronto. September16, 1991, "Lymphoid Lesions: Traps for the Unwary".

17. Victoria Hospital, London, January 1991, "The Immunobiology of Malignant Lymphoma".

18. University of Montreal, Hospital Sainte-Justine. Montreal, October 24,1990, "Simultaneous Phenotype and DNA Analysis of Lymph Node Cell Suspensions".

19. Ontario Medical Association LPTP Symposium, June 1990, Toronto, "Flow Cytometry - Applications in Surgical Pathology and Cytology".

20. Coulter Electronics Quality Control Workshop, May 1990, Toronto, "The Importance of Physician-Technologist Communication in Quality Assurance".

21. St. Joseph's Institute of Laboratory Medicine Symposium, April1990, "Pathology in the 1990's and beyond'.
22. Joint Clinical/Basic Research Symposium, London Regional Cancer Centre, February 7. 1990, "IL-2'Indomethacin Studies: Immunology".

23. Ontario Association of Pathologists Annual Meeting, Niagara-on-the-Lake, October 1989, The Ontario Cancer Foundation Lecturer, "Flow Cytometry: Diagnostic Utility and Pitfalls'

24. Children's Hospital of Western Ontario, LRCC, The University of Western Ontario. September 1989, "Flow Cytometry and Monoclonal Antibodies Recent Developments in Diagnosis of Childhood Cancers'.

25. The Research Institute, St. Joseph's Hospital. April 8,1986. "The Role of Natural Killer Cells in Immune Surveillance and Immunoregulation".

26. Department of Immunology and Microbiology, UWO, January 22, 1985. "Tumour Infiltrating NK Cells"

27. Hematology-Oncology Group, London, 1984, "Host-Response in Malignant Lymphoma".

28. Department of Pathology, McGill University, 1984. 'Natural Killer Cells in Normal and Neoplastic Lymphoid Tissue".

29. Princess Margaret Hospital. Toronto, 1984, "Diagnostic Utility of Immunologic Techniques".

30. Cancer Control Agency of British Columbia and Department of Pathology. Vancouver General Hospital, 1983. "Immunodiagnosis of Cancer".

31. London Cancer Clinic, Ontario Cancer Treatment and Research Foundation, January 1982, "Immunologic Techniques in Pathology".

32. Department of Urology, 1981, "Pathology of the Prostate and Urinary Bladder".
33. Canadian Society for Laboratory Technology, 1981, "Lymphoproliferative Disorders - Current Concepts".

34. London Cytotechnologists' Association, 1980, "The Use of Immunological Markers in the Diagnosis of Lymphoma".

35. Department of Microbiology and Immunology UWO, May 14,1980, "Macrophage Mediated Natural Killing".

**RESEARCH FUNDING: (as principal investigator except where indicated).**

| Title of Proposal | Funding source. | Total amount (CAN$) | Support period |
|---|---|---|---|
| Centre for Molecular Pathology (Co-Investigator with S. Aparicio (PI), Huntsman, D. Horsman, R. Gascoyne) | Canadian Institutes of Health Research (CIHR) | $951,920 | 04/2006 to 03/2011 |
| Validation of reactivity of monoclonal antibodies against cell surface molecules R24.1, R26.8, R23.1 with clinical samples of Hodgkin and non-Hodgkin lymphoma, | Canadian Institutes of Health Research (CIHR) – Proof of Principle grant | $143,575 | 06/2006 to 05/2007 |

| | | | |
|---|---|---|---|
| and demonstration of antibody mediated (PI: Banerjee, D) | | | |
| IN cell analyzer 1000: An integrated and automated digital microscopy unit for the development and analysis of cell-based assays (C-PI: Banerjee, D/ Bally,M/ Burt,HM/ Dedhar,SR/ Dunn,SE/ Huntsman, D/ Karsan, A/ Olive, P/ Pallen C/ Roberge M) | Canadian Institutes of Health Research (CIHR) - Multi-User Equipment & Maintenance Grants Competition | $561,326 | 03/2005 to 02/2006 |
| Clinician Scientists in Molecular Oncologic Pathology (Co-investigator with M-S Tsao) | Canadian Institutes of Health Research (CIHR) | $1,800,000 | 12/2001 to 12/2008 |
| Phase II Trial of Polyphenon E in Former Smokers with Bronchial Dysplasia (Co-investigator with Stephen Lam) . | National Institutes of Health (NIH) (USA) | $12,696,930 | 07/2002 to 06/2007 |
| Development of Custom Array for the Prognosis of Prostate Cancer . (Co-investigatorCo investigator with M Sadar ) | Canadian Institutes of Health Research (CIHR) | $150,000 | 10/2005 to 10/2006 |
| Structure-Function Studies of Cell Surface Molecules R24.1 and R26.8 Expressed by Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma (PI: Banerjee, D) | Canadian Institutes of Health Research (CIHR) | $291,540 | 04/2003 to 06/2006 |
| Oncologic Molecular Microimaging (Project Leader) | Princess Margaret Hospital Foundation | $150,000 | 1999 to 2004 |
| Opportunities in Tumour Banking-bridging no-mans land in cancer research | Canadian Institutes of Health Research (CIHR) | $80,000 | 05/2002 to 04/2003 |
| Clinical and Molecular | National | $909,127 | 04/2000 |

| | | | |
|---|---|---|---|
| Studies of the Tumour Suppressor Gene PTEN in Endometrioid type Endometrial Cancer (Co- principal investigator with A Fyles, M-S Tsao, T Mak) | Cancer Institute of Canada (NCIC) Terry Fox New Frontiers Program | | to 03/2003 |
| Tumour Tissue Repository/Bioinformatics Facility (Co-Principle investigator with Steven Jones) | Western Economic Diversification Canada | $5,100,000 | 03/2002 to 02/2003 |
| Novel Biomarkers and Screening Strategies in Early Detection of Lung Cancer (Co-principal investigator with M-S Tsao, M. Minden. M. Johnston. F. Sheperd) | Princess Margaret Hospital Foundation | $300,000 | 2000 to 2003 |
| Molecular Epidemiology of breast tissue at increased risk of breast cancer (Co-investigator with N. Boyd. E. Fishell. W. Hanna. R. Khokha. N. Miller. R. Jong, D. Tritchler. and M. Yaffe) | Susan G. Komen Breast Cancer Foundation (The) | $245,739 USD | 12/1999 to 12/2001 |
| Prognostic Value of Novel Pathologic Markers in Women with Lymph Node Negative Breast Cancer (Co-investigator with F-F Liu, A Fyles, M Tsao, S Benchimol, D McCready, B Youngson, L Manchul, M Trudeau) | Canadian Breast Cancer Research Initiative | $181,000 | 1998 to 2000 |
| Prognostic Factors for Metastatic Progression of Localized Prostate Cancer (Co-investigator with Drs. S. Narod, M. Jewett. J. Trachtenberg, N. Fleshner. L. Klotz, P. Nam, M. Pollack. L. Kapusta, J. Sweet. U. Slingerland, F. Diamandis) | National Cancer Institute of Canada (NCIC) | $251,179 | 04/1998 to 03/1999 |
| Pathologic Prognostic | Canadian | $333,500 | 1996 |

| | | | | |
|---|---|---|---|---|
| | factors in Early Breast Cancer.(Co-principal investigator with Drs. F.-F. Liu, A. Fyles, M. Tsao, D. McCready) | Breast Cancer Foundation | | to 1997 |
| | Breast Imaging and Breast Cancer Risk (Co-principal investigator with Drs. N. Boyd. A. Belanger, M. Bronskill P. Connelly, H. Draper, F. Fishell. W. Hanna. P. Hegele. R. Jong, A. Miller, D. Tritchler and M. Yaffe) | National Cancer Institute of Canada, Terry Fox Program Project | $1,957,544 | 1994 to 1998 |
| | The Role of Metallothionein in cisplatinum resistance of genitourinary tumours (Co-principal investigator with JL Chin and C Cerian) | Cancer Research Society, Inc. | $120,000 | 1991 to 1993 |
| | Human Monoclonal Anti-bodies from Tumour Infiltrating Lymphocytes | Lawson Research Institute | $27,000 | 1989 to 1990 |
| | Human Monoclonal Anti-bodies Against Lymphoma Antigens | Cancer Research Society, Inc. | $60,000 | 1986 to 1988 |
| | The Role of Natural Killer Cells in the Regulation of Immunoglobulin Synthesis | Med. Res. Council | $ 260,010 | 1985 to 1987 |
| | Naturally Occurring Cell Mediated Cytotoxicity | National Cancer Institute of Canada | $ 321,000 | 1984 to 1987 |
| | Human Monoclonal Anti-body Probes for Lymphoma Associated Antigens. | U.H. Pooled Research | $6,000 | 1985 to 1986 |
| | Host Response in Malignant Lymphoma. | U.H. Pooled Research | $11,000 | 1983 to 1984 |
| | Studies in the Hyper-metabolism of lgG in Myotonic Dystrophy. (With A. Hudson & M. Silver) | Muscular Dystrophy Assoc. of Canada. | $210,000 | 1982 to 1984 |
| | Immunologic Studies in Ulcerative Colitis. | Can. Foundation | $60,390 | 1982 to |

| | | | |
|---|---|---|---|
| | for Ileitis and Colitis | | 1983 |
| Fellowship Grant | Medical Research Council | $30,000 | 1975 to 1977 |

**Full papers in peer-reviewed Journals**:

78. Minglong Zhou, Faisal M Fadlelmola, Jason B Cohn, Brian Skinnider, Randy D Gascoyne and Diponkar Banerjee. Constitutive overexpression of a novel 21 kDa protein by Hodgkin Lymphoma and Aggressive Non-Hodgkin Lymphomas. Mol Cancer 2008, **7**:12 [Epub ahead of print]

77. Fadlelmola FM, Zhou M, de Leeuw RJ, Dosanjh N, Harmer K, Huntsman D, Lam WL, Banerjee D. Sub-megabase resolution tiling (SMRT) array-based comparative genomic hybridization profiling reveals novel gains and losses of chromosomal regions in Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma cell lines. Mol Cancer. 2008 Jan 7;7(1):2 [Epub ahead of print]

76. D Gunn, J Slobodan, C Kamran, J Tzou, David Broemeling, D Banerjee, Andre Marziali. A Novel Applicator Design for Contact-Free Delivery of Aqueous Reagent to Individual Biopsies in a Tissue Microarray. Journal of the Association for Laboratory Automation. 2007. Volume 12, Issue 5, Pages 277-283

75. Slobodan J, Gunn D, Thompson J, Guggenheimer K, Brown K, Homenuke M, Belak R, Banerjee D, Broemeling D, Marziali A. An automated nanoliter dispenser for staining individual biopsies in tissue microarrays. Int J Oncol. 2007 Apr;30(4):857-63.

74. Wei Shi, Xinghe Zhang, Melania Pintilie, Nacy Ma, Naomi Miller, Diponkar Banerjee, Ming-Sound Tsao, Tak Mak, Anthony Files, Fei-Fei Liu. Dysregulated pten-pkb and negative receptor status in human breast cancer. Int J Cancer 104:195-203, 2003.

73. Parker C, Milosevic M, Panzarella T, Banerjee D, Jewett M, Catton C, Tew-George B, Gospodarowicz M, Warde P. The prognostic significance of the tumour infiltrating lymphocyte count in stage I testicular seminoma managed by surveillance. Eur J Cancer 38: 2014-2019, 2002.

72. Banerjee D. The Molecular Biology of MALT Lymphomas. Hematología Citocinas, Inmunoterapia y Terapia Celular. 5: 93-102; 2002

71. Poussier P, Ning T, Banerjee D, Julius M. A unique subset of self-specific intraintestinal T cells maintains gut integrity. J Exp Med. 2002 Jun 3;195(11):1491-7.

70. Guo YP, Martin LJ, Hanna W, Banerjee D, Miller N, Fishell E, Khokha R, Boyd NF. Growth factors and stromal matrix proteins associated with

mammographic densities. Cancer Epidemiol Biomarkers Prev. 2001 Mar;10(3):243-8.

69. Joseph MG, Banerjee D, Kocha W, Feld R, Stitt LW, Cherian MG. Metallothionein expression in patients with small cell carcinoma of the lung. Cancer 2001, 92:836-842

68. Al-Maghrabi J, Kamel-Reid S, Jewett M, Gospodarowicz M, Wells W, Banerjee D. Primary low grade B-cell lymphoma of MALT type arising in the urinary bladder: report of four cases with molecular genetic analysis. Arch Pathol Lab Med March 2001. 125: 332-336

67. Milosevic MF, Warde PR, Banerjee D, Gospodarowicz MK, McLean M, Catton PA, Catton CN. Urethral carcinoma in women: results of treatment with primary radiotherapy. Radiother Oncol. 2000 Jul 1;56(1):29-35.

66. Poussier P, Ning T, Chen J, Banerjee D, Julius M. Intestinal inflammation observed in IL-2R/IL-2 mutant mice is associated with impaired intestinal T lymphopoiesis. Gastroenterology. 2000 May;118(5):880-91.

65. Chan S., Hutnik CML, Heathcote, JG, Orton RB, Banerjee. D. Primary iris lymphoma in a pediatric cardiac transplant recipient: Clinicopathologic findings Ophthalmology. 2000 107(8):1479-82

64. E. C. LaCasse, MR. Bray, B. Patterson, W.-M. Lim, S. Perampalam, L. C. Radvanyi, A. Keating, AK. Stewart, R. Buckstein, J.S. Sandhu, N. Miller, D. Banerjee D., Singh, AR. Belch, L.M. Pilarski, and J. Gariepy. Shiga-Like Toxin-I Receptor on Human Breast Cancer, Lymphoma. and Myeloma and Absence From CD34+ Hematopoietic Stem Cells: Implications for Ex Vivo Tumour Purging and Autologous Stem Cell Transplantation. Blood. 1999:94: 2901-2910

63. Marks A. Sutherland DR Bailey D, lglesias 4, Law 4. Lei M. Yeger H, Banerjee D, Baumal P Characterization and distribution of an oncofetal antigen (M2A antigen) expressed on testicular germ cell tumours. *Br J Cancer* 1999; 80 :569-78

62. Spaner D., Lowsky P. Fyles C, Lipton J.H., Banerjee D., Ng C.M., Wade J.A. Messner H.A. Acute intestinal graft-versus-host disease in a syngeneic bone marrow transplant recipient. Transplantation 1998 66:1251-3.

61. Siu L., Banerjee D., Khurana P., Pan X., Pflueger R,. Tannock I., Moore M. The Prognostic Role of p53, Metallothionein, p-glycoprotein and MB-1 in Muscle-Invasive Urothelial Transitional Cell Carcinoma. Clinical Cancer Research, 4,559-565, March 1998.

60. Hodgson D., Chow E., Jenkin D., Danjoux C., Greenberg M., Banerjee D., Williams T., Shandling B., Babyn P. Metastatic nonfunctional retroperitoneal paraganglioma. Med Pediatr Oncol. 1998 Mar;80(3):187-

92.

59. McLean M., Srigley J., Banerjee D., Srigley J., Warde P., Hao Y. Interobserver variation in Gleason scoring: are there implications for the design of clinical trials and treatment strategies? Clinical Oncology (1997) 9:222-225.

58. Warde P., Gospodarowcz M., Panzarela T., Banerjee D., Sugar L., Catton C. Sturgeon J., Moore M., Jewett M. Prognostic Factors for Relapse in Stage I Testicular Seminoma Managed by Surveillance. Urol. 1997 May:I57(5):1705-9

57. Kwan W., Liu F.F., Banerjee D., Rotstein L., Tsang P. Mixed papillary and squamous carcinoma of the thyroglossal duct cyst: a case report. Canadian Journal of Surgery. No. 89, No.4, August 1996.

56. Banerjee D. Flow cytometry related to hematopoietic malignancy. Trans. Sci. Vol. 16, No.3, pp. 815-820, 1995.

55. Tsang R.W., Fyles A.W., Kirkbride P., Levin W., Manchul L.E., Milosevic M.F., Rawlings G.A., Banerjee D., Pintilie M., Wilson G.D. Proliferation measurements with flow cytometry TPOT in cancer of the uterine cervix: Correlation between two laboratories and preliminary clinical results. Int. J. Radiation Oncology Biol. Phys., Vol. 32, No.5, pp. 1319-1329, 1995.

54. Joseph M.G., Banerjee D., Harris P., Gibson S., McFadden R.G. Multiparameter flow cytometric DNA analysis of effusions: A Prospective Study of 36 cases compared with routine cytology and immunohistochemistry. Modern Pathology, Vol. 8. No. 6, pp. 686-693, August 1995.

53 Mertens W.C., Banerjee D., Al-Mutter N., Stilt L., Bramwell V.H.C., Lala P.K. High dose continuous venous infusion Interleukin-2: Influence of dose arid infusion rate on tumoricidal function and lymphocyte subsets. Cancer Immunol. Immunother. (1995) 41:271-279.

52. Griesser H., Henry M., Boie D., Banerjee D. Large cell anaplastic lymphoma of the gastrointestinal tract - an immunohistochemical and genotypic study on archival material. Hematol. Patho. 8:121 -1 34, 1994.

51. Ahern V., Jenkin D., Banerjee D., Greenberg M., Payne D. Nasopharyngeal carcinoma in the young. Clinical Oncology (1994) 6:24-30.

50. Chin J.L, Banerjee D., Kadhim S.A., Kontozoglou T.E., Chauvin P.S Cherian P.J. Metallothionein in testicular germ cell tumors and drug resistance; Clinical correlation. Cancer, Vol. 72, No. 10, pp. 3029-3035. November15, 1993

49. Mertens W.C., Bramwell V.H.C., Banerjee D., Gwadry-Sridhar F., Al-Mutter N., Parhar R.S., Lala P.K. Sustained oral Indomethacin and

Ranitidine with intermittent continuous infusion Interleukin-2 in advanced renal cell carcinoma, Cancer Biotherapy, Vol.8, Number 3, 229-233, 1993.

48. Banerjee D. et al. Letter to the Editor: Regarding "Acute basophilic leukemia and acute eosinophilic leukaemia after therapy for non-Hodgkin's lymphoma. Am. J. Clin, Pathol. 1993; 96:160-170.

47. Mertens W.C., Bramwell V.H.C., Banerjee D. Gwadry-Sridhar F., Lala P.K. Sustained Indomethacin and Ranitidine with Intermittent Continuous Infusion Interleukin-2 in Advanced Malignant Melanoma: A phase II study. Clinical Oncology (1993) 5:107-113.

46. Mertens W.C., Bramwell V.H.C., Lala P.K., Banerjee D., Gwadry-Sridhar F., Romano W. Continuous Indomethacin and Ranitidine with Interleukin-2 in advanced renal carcinoma and melanoma: A preliminary report. Can. J. Infect. Dis., Vol.3, Suppl. B. 133B-137B, Aug. 1992.

45. Lapointe H., Lampe H., Banerjee D. Head and neck squamous cell carcinoma cell line-induced suppression of in vitro lymphocyte proliferative responses. Otolaryngology - Head & Neck Surgery 106:149-158, 1992.

44. Mertens W.C., Bramwell V.H.C., Gwadry-Sridhar F., Romano W., Banerjee D., Lala P.K. Effect of Indomethacin plus Ranitidine in advanced melanoma patients on high dose Interleukin-2. The Lancet, Vol. 340, pp. 397-398, August 15,1992.

43. Chernoff W.G., Lampe HR, Cramer H., Banerjee D. The potential clinical impact of the fine needle aspiration/flow cytometric diagnosis of malignant lymphoma. Journal of Otolaryngology. Vol. 21, Suppl. 1:1-15, 1992.

42. Banerjee D. The role of molecular biology in the pathology department of a teaching hospital. The Canadian Journal of Oncology. Vol.2, No.2. pp 96-100, 1992.

41. Cherian MG., Banerjee D. Immunohistochemical localization of metallothionein. Methods in Enzymology 205:88-95, 1991.

40. MacRae J.D., Lampe H., Banerjee D. Blood transfusions and phenotypic immune profile in head and neck cancer patients undergoing surgical resection. Journal of Otolaryngology 20:310-314, 1991.

39. Bahnson R.R., Banner B.F., Ernstoff MS., Lazo J.S., Cherian MG., Banerjee D., Chin J.L. Immunohistochemical localization of Metallothionein in human bladder transitional cell carcinomas. Journal of Urology 146:1519-1520, 1991.

38. Zanyk M.J., Banerjee D., Hearn S. Immunogold labelling of tumour cells during NK/Target coil interactions. Cytopathology 1:105-117,1990.

37. Zanyk M.J., Banerjee D., McFarlane D.L. A flow cytometric assay for target binding by NKH1 A4- cells, using a single laser system. Analytical Cellular Pathollogy2:241-251, 1990.

36. Banerjee D., Walton J.C., Jory T.A., Crukley C, Meek M. Primary gastric T cell lymphoma of suppressor-cytotoxic (CDS-t-) phenotype: Discordant expression of T cell receptor subunit El, CD7 and CD3 antigens. Human Pathology 21:872-874, 1990.

35. Lampe H., Lapointe H., Cramer H., McFarlane D., Banerjee D. Whole cell preparation of squamous cell carcinoma for flow cytometric analysis of DNA. Otolaryngology-Head and Neck Surgery 103:72-79, 1990.

34. Banerjee D., Karim R., Hearn S.: Geddes D. Human monoclonal antibodies to neuroendocrine granules derived from tumour-infiltrating lymphocytes isolated from a primitive neuroendocrine tumour. Human Antibodies and Hybridomas 1:55-63, 1990.

33. Banerjee D., Mils D.M., Hearn S.A., Meek M., Turner, K.L. Proteinaceous lymphadenopathy due to monoclonal non-amyloid immunoglobulin deposit disease. Archives of Pathol. & Lab. Med. 114:34,1990.

32. Kontozoglou T.E., Banerjee D., Cherian, M.G. Immunohistochemical localization of metallothionein in human testicular embryonal carcinoma cells. Virchows Archiv. A. Pathol. Anat. (1989) 415:545-549. -

31. Flanagan P.R., Lam D., Banerjee D., Valberg, E.S. Ferritin release by mononuclear cells in hereditary hemochromatosis. J. Lab. Clin. Med. Vol. 113, No.2, pp 145-150. February 1989.

30. Zanyk M.J., Banerjee D., McFarlane D.L. Flow cytometric analysis of the phenotypic changes in tumour cell lines following TPA induction. Cytometry 9:374-379, 1988.

29. Zanyk M.J., Banerjee D., McFarlane D.L. Transferrin receptor (TfR) and 4E2 expression by NK-sensitive and NK-resistant tumour cell lines. Carcinogenesis 9:1377-1361, 1988.

28. Nartey N.O., Banerjee D., Cherian M.C. Immunohistochemical localization of metallothionein nucleus and cytoplasm of fetal human flyer and kidney and its changes during development. Pathology 19, pp 233-238 1987

27. Banerjee D. Phenotypic and functional analyses of tumour-infiltrating Leu7 4- natural killer-like cells in non-Hodgkin's lymphomas. Cancer Detect. & Prevent. Supplement 1:103-109, 1987.

26. Nartey N.O., Cherian M.G., Banerjee D. Immunohistochemical localization of metallothionein in human thyroid tumours. Am. J. Patho.l29:I77-182. 1987.

25. Cherian M.G., Templeton D.M. Gallant K.R., Banerjee D. Biosynthesis

and metabolism of metallothionein in rat during perinatal development. Experientia Supplementum Vol. L2Metallothionein IJ Ed JHR. Kagi. Y. Kojima. Birkhauser Verlag Basel, pp 499-505. 1987.

24. Hudson AU., Huff MW. Wright 0.0., Silver M.M., Lo, T.C.Y., Banerjee D. The role of insulin resistance in the pathogenesis of myotonic muscular dystrophy. Brain 110:469-488, 1987.

23. Grignon D.J., Banerjee D. Cross reactivity of a monoclonal pan T-cell antibody (Anti-Leu 4) with prostate epithelium. J. UroI. 137:330-332, 1987.

22. Banerjee D., Flanagan P.R., Cluett J., Valberg L.S. Transferrin and transferrin receptors in the human gastrointestinal tract: Relationship to body iron stores. Gastroenterol. 91:861-869,1986.

21. Silver M.M., Hudson A.J., Vilos G.A., Banerjee D. Hyperinsulinemia in myotonic dystrophy: Identity ot the maternal factor causing the neonatal myotonic dystrophy syndrome. Medical Hypoth. 16:207-220. 1985.

20. Devineni R, McKenzie N., Keown P., Stiller C., Hellstrom A., Banerjee D. Immunologic monitoring in cardiac transplantation. Transplantation Proceedings XVI(6):1 576-15479 1984

19. Banerjee D. Letter to the Editor: Regarding "A comparison between a modified avidin-biotin-immunoperoxidase system and flow cytometry". The Journal of Histochemistry and Cytochemistry 32:1243,1984.

18. Templeton D.M., Banerjee D., Cherian M.D. Metallothionein synthesis and localization in relation to metal storage in rat liver during gestation. Can. J. Biochem. & Cell Biol. 63:16-22, 1984.

17. Ko H.S., Ohene-Fianko D., Banerjee D. Responsiveness of T-lymphocytes subpopulations in autologous mixed lymphocyte reaction autologous reactivity lies chiefly in a low-density cell fraction. Cell Immunol. 85:258-263, 1984.

16. Banerjee D., Petit S. Endogenous avidin-binding activity in human lymphoid tissue. J. Clin. Pathol. 37:223-225, 1984

15. Ko H.S., Banerjee D. Macrophage function in common variable immunodeficiency. Letter to the Editor, NEJM 308:286, 1983.

14. Banerjee D., Thibert R.F. Natural killer-like cells found in B cell compartments of human lymphoid tissues. Nature 304:270-272. 1983.

13. Michaud U., Banerjee D., Kaufmann J.C.E. Lymphomatoid granulomatosis involving the central nervous system: complication of a renal transplant with terminal monoclonal B cell proliferation. Acta Neuropath. 61:141-147, 1983.

12. Silver M.M., Banerjee D., Hudson A.J. Segmental myofibre necrosis in myotonic dystrophy: an immunoperoxidase study of immunoglobulins in

skeletal muscle. Am. J. Pathol. 112:294-301, 1983.

11. Panemangalore M., Banerjee D., Onosaka A., Cherian M.G. Changes in the intracellular accumulation and distribution of metallothionein in rat liver and kidney during postnatal development. Develop. Biol. 97:95-102, 1982.

10. Banerjee D., Silver M.M., McClintock J., Hudson A. Monocyte IgG Fc receptors in myotonic dystrophy. Olin, Exp. Immunol. 50:572-578, 1982.

9. Banerjee D., Onosaka S., Cherian M.G. Immunohistochemical localization of metallothionein in cell nuclei and cytoplasm. Toxicology 24:95-lOS, 1982

8. Banerjee D., Ahmad D. Malignant lymphoma complicating lymphocytic interstitial pneumonia.
Human Pathol. 112:780-782, 1982.

7. Wright B., Wysocki G.P., Banerjee D. The diagnostic use of immunoperoxidase techniques in plasma cell lesions of the jaws. Oral Surg. 52:615-622, 1981.

6. Richter M., Banerjee D., Sklar S. The antibody independent naturally occurring cellular cytotoxic (NOCC) activity of normal circulating human leukocytes. II. Failure to detect effector cell-target cell interaction and target specificity of the circulating cytotoxic-enhancing factor. Immunology 44:109-118,1981.

5. Banerjee D., Fernando L., Richter M. The antibody-independent naturally-occurring cellular cytotoxic (NOCC~ activity ot normal circulating human mononuclear cells. I. The role of serum and the nature ot the target cells in the NOCC assay. Immunology 44:97-108, 1981.

4. Banerjee D., Silva F. Mediastina] mass with acute leukaemia. Myeloblastoma masquerading as lymphoblastic lymphoma. Archives of Pathology and Laboratory Medicine 105:1126-129,1981.

3. Banerjee D., Hamdy H., Formanis J., Walter T., Richter H. Leukemic reticuloendotheliosis: polyclonal surface immunoglobulin in "Hairy" cells. Cancer 41:1804-1810,1978.

2. Behelak Y.B., Banerjee D., Richter M. Immunocompetent cells in man. I. the lack of naturally occurring killer cell activity in patients with chronic lymphatic leukemia. Cancer 38:2274-2277. 1976.

1. Mckhann C.F., Hendrickson C.G., Spitler L.E., Gunnarsson A., Banerjee D., Nelson W.R. Immunotherapy of melanoma with BOG: Two fatalities following intralesional injection. Cancer 35:514-520, 1975.

**Abstracts:**

89. Faisal Fadlelmola, Minglong Zhou, Ronald J. de Leeuw, Pedro Farinha,

Christian Steidl, Randy Gascoyne, Wan Lam, and Diponkar Banerjee. Brd2 gene and protein expression in malignant lymphoma. Accepted for platform presentation, International Conference on Burkitt Lymphoma and Related Lymphoproliferative Disorders. February 25-27, Kampala, Uganda.

88. Faisal M. Fadlelmola, Minglong Zhou, Ronald J. de Leeuw, Nirpjit Dosa Karynn Harmer, David Huntsman, Wan L. Lam and Diponkar Baner Sub-Megabase Resolution Tiling (SMRT) Array-Based CGH Profiling Gene Expression Data Patterns in Hodgkin Lymphoma and Anaplastic La Cell Lymphoma Cell Lines. Abstract #1922. XXVI Congress of International Academy of Pathology. September 16-21, 2006. Montr Quebec.

87. Minglong Zhou, Faisal M. Fadl El Mola, Jason B. Cohn, Pedro Farinha, Randy D. Gascoyne, Brian F. Skinnider, Diponkar Banerjee. Novel Murine Monoclonal Antibodies anti-R23.1, anti-R24.1 and anti-R26.8 Recognize Epitopes Distinct from CD30, Constitutively Over-Expressed by Hodgkin/Reed-Sternberg and Anaplastic Large Cell Lymphoma Cells. BC Cancer Agency, Vancouver, BC, Canada, Samuel Lunenfeld Research Institute. 2006 AACR Annual Meeting. April 1, 2006., Washington, DC. Toronto, Ontario, Canada.

86. Minglong Zhou1, Faisal M. Fadl El Mola1, Hong Chang, Jason Cohn, Riyez Karim, Donna Hogge, and Diponkar Banerjee. Cell Surface Molecule R9.14 is Expressed by Monoblastic Leukemia of FAB M5 Type as well as Reed-Sternberg Cell Lines and Anaplastic Large Cell Lymphoma Cell Lines. 2006 USCAP Annual Meeting. February 11-17, 2006, Atlanta, GA.

85. Faisal M. Fadl El Mola, Minglong Zhou, Ronald J. de Leeuw, Nirpjit Dosanjh, Wan L. Lam, Diponkar Banerjee. Functional Characterization of Pathways Triggered by a Novel Cell Surface Antigen (R26.8) Expressed by Hodgkin Lymphoma & Anaplastic Large Cell Lymphoma using cDNA Microarrays and Array-CGH. American Association of Cancer Research; Molecular Targets and Cancer Therapeutics, November 15, 2005, Philadelphia, Pennsylvania.

84. Brian F. Skinnider, Achim A. Jungbluth, Diponkar Banerjee, Randy D. Gascoyne. MAGE-A4 Expression in Hodgkin's Lymphoma (HL) and Non-Hodgkin's Lymphoma (NHL). United States and Canadian Academy of Pathology 90th Annual Meeting, March, 2001. Modern Pathology 14: 179A, 2001 (Abstract).

83. Banerjee D., Cohn J., Karim P.
Effects of novel monoclonal antibodies against KMH2 cells on proliferation of Hodgkin cell lines. American Association for Cancer Research. San Francisco April 1-5, 2000.

82. Banerjee D., Cohn J, Karim R.
Novel monoclonal antibodies against Hodgkin cell line KMH2 recognize epitopes distinct from CD30. United States and Canadian Academy of Pathology 89th Annual Meeting, March 25-31, 2000, New Orleans.

81. AL-Maghrabi J, Reid S.K. Jewett M, Gospodarowicz M. Banerjee D. Primary low grade B-coil lymphoma of MALT type of the urinary bladder: report of four cases with molecular genetic analysis. United States and Canadian Academy of Pathology 89th Annual Meeting, March 25-3], 2000, New Orleans.

80. Banerjee D., Karim P. New Monoclonal antibodies reactive against Hodgkin's coil line KMH2. European Congress of Pathology, Barcelona. Spain, September 18-23, 1999.

79. Poussier P., Ning T., Chen J., Banerjee D., and Julius M. Lack of Intestinal T Lymphopoiesis in IL-2P$_1$3 Deficient Mice is Associated with Acute Lesions of Enteropathy and Colitis. Inflammatory Bowel Disease Research Meeting (Crohn's and Colitis Foundation of Canada), Hockley Valley Resort and Conference Centre, April 8-11 1999.

78. Joseph MG., Banerjee D., Kocha W., Feld P., and Cherian M.G. Metallothionein, PCNA, p53, and retinoblastoma gene product expression In small cell carcinoma of the lung: correlation with clinical outcome. United States and Canadian Academy of Pathology 87th Annual Meeting, Boston. February 23-March 6,1998.

77. Banerjee D., Harris P., Taylor M. S-Phase Fractions of Non-Neoplastic Lymphocytes Parallel Those of Neoplastic Cells in Intermediate and High Grade Non-Hodgkin's Lymphomas. Royal College of Physicians and Surgeons of Canada Meeting, September 25-28, 1997, Vancouver. British Columbia.

76. LaCasse E., Paterson B., Saleh M., Banerjee D., Gariepy J. CD77 Detected by FITC Labelled Shiga-Like Toxin on Follicle Centre Cell Lymphomas: A Potential Target for Ex Vivo Stem Cell Purging. Leukemia Research Fund of Canada, Frontiers of Malignant Hematology, June 5-7, 1997, Toronto, Ontario.

75. Siu L., Moore M., Khurana R., Pan X., Pflueger R., Tannock I., Banerjee D. Metallothionein (MT) Expression Predicts for Response to Chemotherapy in Patients with Urothelial Tract Cancer. ASCO Annual Meeting, May 17-20, 1997. Denver, Colorado.

74. McLean M., Banerjee D., Richmond H., Abdolell M. Gleason Scores: Interobserver Variation and Implications fro Clinical Trials. Royal College of Physicians and Surgeons of Canada meeting, Sept. 26, 1996, Halifax. Abstract in Clin. Invest. Med.

73. Banerjee D., Warde P., Gospodarowicz M.K., Kockebakker M., Webster L.A, Panzarella T. Sugar L., Catton CNJ., Sturgeon J.F.D.G., Moore M., Jewett M.A.S. Stage I testicular seminoma managed by surveillance alone: Is flow cytometric DNA analysis of predictive value for relapse? 85th Annual

Meeting, US. & Canadian Academy of Pathology, Washington, D.C., March 23-29, 1996.

72. Banerjee D., Karim P., Griesser H.
Murine monoclonal antibodies reactive against Hodgkin's Disease cell lines and large cell anaplastic lymphoma lines: Initial characterization of three new antibodies.
XXIII Meeting of the International Society for Oncodevelopmental Biology and Medicine,
Montreal, September 10-13, 1995.

71. Banerjee D., Karim P.
Initial characterization of a human MAb, derived from unimmunized normal peripheral blood lymphocytes, reactive against adenocarcinoma cells. LV International Conference on Human Antibodies and Hybridomas, Amsterdam, The Netherlands, April 26-28, 1995.

70. Banerjee D., Harris P., Taylor M.
S-Phase analysis in non-Hodgkin's lymphoma: effect of correcting for non-neoplastic bystander cells. XVI International Cancer Congress! New Delhi, India, October 30-November 5,1994.

69. Banerjee D.
Technological advances in the diagnosis of cancer and their potential impact on cancer registration. American Association of Central Cancer Registries, Niagara-on-the-Lake, Ontario, April 27-29, 1994.

68. Chapman W.B., Levin W., Banerjee D., Fyles W., Rosen B.
Ovarian granulosa cell tumours - A clinicopathologic analysis of 43 cases. US. & Canadian Academy of Pathology, San Francisco, California, March 12-16, 1994.

67. Banerjee D., Harris P., Taylor M.
S-phase analysis in non-Hodgkin's lymphoma: subset restricted analysis reveals marked heterogeneity within histological grades. U.S. & Canadian Academy of Pathology, San Francisco, California, March 12-18, 1994.

66. Mertens W.D., Banerjee D., Gwadry-Sridhar F., Bramwell V., Lala P.K.
High dose continuous venous infusion Interleukin-2 (1L2) in renal carcinoma and melanoma: influence of delivered dose (DO) and infusion rate (IR) on lymphocyte subsets. ASCO Annual Meeting, Dallas. Texas, May 14-17. 1994.

65. Ahern V., Jenkin D., Banerjee D., Greenberg M., Payne D.
Nasopharyngeal carcinoma in the young. Annual Meeting of Royal[ College of Radiologists, Warwick, England, September 1993.

64. Joseph MG., Banerjee D., Harris P., Gibson S., McFadden P. Prospective study of body cavity fluids by concurrent multiparameter flow cytometry and routine cytology. XVI Congress of the International Society for Analytical Cytology, March 21-26, IPSO. Colorado Springs, Colorado, U.S.A.

63. Banerjee D., Cramer H.M., Lampe H.B.
Flow cytometric phenotyping of FNAB samples of lymphoid lesions: Are the results reliable? Second Conference of the European Society for Analytical Cellular Pathology, May 17-22, 1992, Nijmegen, The Netherlands.

62. Chernoff W.G., Cramer H., Lampe H.B., Banerjee D.
The potential clinical impact of the fine needle aspiration/flow cytometric diagnosis of malignant lymphoma. Proceedings of the Annual Meeting of the Canadian Society of Otolaryngology - Head and Neck Surgery, Edmonton, Alberta,. June 1991.

61. Banerjee D, Mertens W, Bramwell V, Lala PK. Sequential changes in lymphocyte subsets in patients on chronic indomethacin plus IL-2 therapy for advanced cancer. Proc Amer Assoc Cancer Res 1991; 32: 247

60. Banerjee D., Mertens W., Bramwell V., Lala P.K.
Correlation of lymphocyte phenotypic changes with clinical responses to chronic oral indomethacin and intravenous IL-2 therapy in advanced melanoma and renal carcinoma patients. Institute for Advanced Studies in Immunology and Aging.
First International Symposium on Combination Therapies. Washington, DC., March 14 and 15,1991.

59. Lala P.K., Mertens W., Bramwell V., Banerjee D., Al-Mutter N.
Relationship of in vitro tumoricidal function of lymphocytes with clinical responses to chronic oral indomethacin and intravenous IL-2 therapy in advanced melanoma and renal carcinoma patients. Institute for Advanced Studies in Immunology and Aging.
First International Symposium on Combination Therapies. Washington, D.C., March14 and 15, 1991.

58. Lala P.K., Mertens W., Bramwell V., Banerjee D., Al-Mutter N.
Correlation of in-vitro tumoricidal function of lymphocytes t in-vivo responses to chronic oral indomethacin therapy and intravenous IL-2 in melanoma and renal cell carcinoma patients. Proc Amer Assoc Cancer Res 1991; 32: 248.

57. Hearn S.A., Banerjee D., Karim R.
Localization of Chromogranin A in human neuroblastoma cell lines by post-embedding immunoelectron microscopy. Soc. Histochem. Cytochem., August 1990, Seattle.

56. O'Malley F., Cramer H., Banerjee D. Lampe H.
Flow cytometry of lymphoid fine needle aspirates: an improvement in Diagnostic Accuracy. U.S-Can. Acad. ot Pathology, Annual meeting, March 1990, Boston.

55. Harris W.P., McFarlane D.I., Banerjee D.
Surface immunoglobulin light chain expression in lymph node cells - comparison of kappa:lambda ratios and relative antigen density in monoclonal and polyclonal populations. XIV International Meeting,

Society for Analytical Cytology. North Carolina, March 1990.

54. Lapointe H.J., Lampe H., Banerjee D.
Expansion of tumour-infiltrating lymphocytes (TIES) from squamous cell carcinoma of the Head and neck: synergistic effect of indomethacin and irradiated autologous feeder layers on PHA and IL-2 driven proliferation. Ninety Third Annual Meeting of the American Academy of Otolaryngology-Head and Neck Surgery, September 1989, New Orleans, Louisiana.

53. Banerjee D., Kumalo T.G.
T cell lymphoma and hemophagocytic syndrome. CAP 52 nd Annual Meeting, Niagara-on-the-Lake, October 1989.

52. Lala P.K., Parhar R.S., Mertens W., McFarlane D., Banerjee D.
Phenotypic and functional changes in lymphocytes in cancer patients during chronic indomethacin and intermittent IL-2 therapy. Proceedings of the Canadian Federation of Biological Societies,
Calgary. V.32. pp 123, June 1989.

51. Lala P.K., Parhar R.S., Mertens W., McFarlane D., Banerjee D.
Functional and phenotypic changes in lymphocyte populations in cancer patients on chronic indomethacin + IL-2 therapy. Proceedings of the American Association for Cancer Research, Inc.,
San Francisco, V. 30. pp 379, May 1989.

50. Lala P.K., Parhar R.S., Mertens W., Banerjee D.
Lymphocyte phenotype and function in cancer patients during chronic indomethacin plus intermittent IL-2 therapy. Proceedings of the 7th International Congress of Immunology, Berlin, pp 754, July 30-August 5,1989.

49. Chin J.I., Banerjee D., Cherian G., Kontozoglou T., Kadhim S.A.
Role of metallothioneins in germ cell tumour behaviour: experimental and clinical evidence.

48. Banerjee D., Parhar R.S., Mertens W., McFarlane D.L., Lala P.K.
Sequential changes in lymphocyte subsets in patients on chronic indomethacin + IL-2 therapy for advanced cancer. Symposium on Immunobiology in Clinical Oncology and Immune Dysfunctions,
Nice, France, April 9-11,1989.

47. Lala PK, Parhar RS, Mertens WC, Banerjee D. Lymphocyte phenotype and function in cancer patients during chronic indomethacin plus intermittent IL-2 therapy. Proc Int Congress Immunol, 1989: 7:754

46. Lala PK, Parhar RS, Mertens W, McFarlane D, Banerjee D. Phentypic and functional changes in lymphocytes in cancer patients during chronic indomethacin and intermittent IL-2 therapy. Proc. Can Fed Biol Soc 1989, 32

45. Lala PK, Parhar RS, Mertens W, McFarlane D, Banerjee D. Effects of chronic indomethacin therapy combined with multiple rounds of IL-2 on

lymphocyte phenotype and function in patients with advanced cancer placed on a phase II trial. Critical determinants in cancer progression and metastases. Houston, Texas 6-9 March 1989.

44. Lala P.K., Parhar R.S., Mertens W., McFarlane D., Banerjee D.
Functional and phenotypic changes in lymphocyte populations in cancer patients on chronic indomethacin + IL-2 therapy. American Association for Cancer Research, 30: 379,1989.

43. Fardy J., Lloyd D.A., Reynolds R.P.E., Banerjee D., Hammerberg O., Gopaul D.
The role of campylobacter-like organisms in symptomatic post-gastrectomy patients. Royal College Meeting, 1989

42. Mertens W, Bramwell V, Levin L, Lala P, Banerjee D. Recombinant interleukin 2 (RIL-2) and indomathacin: A new approach to cancer immunotherapy. In: Cancer in Ontario pp 168-169, 1988

41. Banerjee D., Karim R., Geddes D.
Construction of human-human hybridomas from tumour-infiltrating B cells. 8th International Congress of Histochemistry and Cytochemistry, Washington, August 1988.

40. Hearn S.A., Banerjee D., Nartey N., Cherian M.G.
Ultrastructural localization of metallothionein in rat liver, human thyroid tumors and a test substrate with the protein A-gold technique. 8th International Congress of Histochemistry and Cytochemistry, Washington, August 1988.

39. Lampe H., Lapointe H., Cramer H., Hanas C., McFarlane D., Banerjee D.
Whole cell preparation for flow cytometry. 2nd International Conference on Head and Neck Cancer,
Boston, Mass., July 31 -August 5, 1 938.

38. Cherian M.G., Banerjee D.
Regulation of the ontogenic expression of mammalian metallothionein and its presence in tumours. 14th International Congress of Biochemistry, Prague, Czechoslovakia, July 10-15,1988.

37. Kumalo T., Cramer H., Lampe H., McFarlane D., Hanas C., Banerjee D.
The use of fine needle aspiration and flow cytometry in the diagnosis of lymphoid processes. Presented at the Joint Meeting of the Canadian Congress of Laboratory Medicine and the Canadian Society ot Clinical Chemists Association of Pathology, Winnipeg, Manitoba, June 1988, Proceeding of the 1983
Joint Meeting of the CCLM/CSCC, p. 62,1988.

36. Lapointe H.J., Banerjee D., Lampe H.
Irradiated vs. non-irradiated squamous cell carcinoma of the head and neck: correlation of histologic lymphocyte infiltration and response to exogenous IL-2 in vitro.
Lab. Invest. 58:SSA. 1988. Presented at NP., Washington, March 1, 1988.

CURRICULUM VITAE

UPDATED 23-JUL-08

35. Lapointe H.J., Banerjee D., Lampe H.
The establishment of conditions for the enzymatic liberation of tumour infiltrating lymphocytes from head and neck squamous cell carcinoma and their subsequent growth in culture. Presented at 19th International Leucocyte Culture Conference, Banff. Alberta. May 6-12, 1988.

34. Zanyk M., Banerjee D., McFarlane D., Hearn S.
An investigation into the role of transferrin receptors in NK/Target interactions.
Presented at 19th International Leucocyte Culture Conference, Banff, Alberta, May8-12, 1988.

33. Banerjee D., Baril J., Bell D.A., McFarlane D.
Suppression of immunoglobulin production by germinal centre HNK-1+ CD3+ cells 9th International Conference on Lymphatic Tissues and Germinal Centres in Immune Reactions, Oslo, Norway, August 1987.

32. Zanyk M., Banerjee D., McFarlane D.
TPA-induced resistance of K562 cells to NK-mediated cytolysis correlates with decreased expression of the transferrin receptor. Biology of Growth Factors, Triennial Symposium, Toronto. June 17-19, 1987.

31. Banerjee D., DeVeber L.L., Chottuck D., McFarlane D.
Monitoring of remission status in children with acute lymphocytic leukaemia by sequential bone marrow analysis. First Annual Meeting Clinical Application of Cytometry,
Charleston, South Carolina, September 30-October 3,1986.

30. Banerjee D.
Characterization of tumour-infiltrating human natural killer cells in malignant lymphomas by the two colour flow cytometry. international Symposium on Immunobiology of Cancer and Allied Immune Dysfunctions, Copenhagen, Denmark, November 4, 1985.

29. Grignon D., Banerjee D.
Cross reactivity of a monoclonal pan T-cell antibody with prostate epithelium. Canadian Congress of Laboratory Medicine. June 22-26, 1986, Edmonton. Alberta.

28. Banerjee D., Thibert R.F.
Tumour-infiltrating NK cells in large cell lymphomas express both T cell and myeloid antigens. Paper presented at Brit. Soc. Immunol. Meeting, November 8,1984, London, England.

27. Banerjee D.
Co-expression of Pan-T antigen cells in human lymphoid tissue. LTH Congress of the European Society for Pathology, Hamburg. Germany, September 1983. Pathol. Res. Pract. 178:110, 1982.

26. Banerjee D.
Simultaneous identification of 1-helper/inducer and T-suppressor/cytotoxic lymphocytes in human intestinal mucosa by two colour fluorescence. Lab. Invest. 48:6A, 1983.

25. Cherian M.G., Panemangalore M., Banerjee D.
Disposition of metallothionein in rat liver during postnatal development. The Toxicologist 3:75. 1983.

24. Ko H.S., Banerjee D.
Variation of T cell subsets and mitogen stimulation in immunodeficiency and cancer.
Annual Meeting, Royal Coil. Phys. Surg. Canada, Quebec City, September 1982.

23. Silver M.M., Banerjee D., Hudson A.J.
Immunoglobulins in skeletal muscle - an immunoperoxidase study. Poster session.
Canadian Congress of Laboratory Medicine, Vancouver, June 1982.

22. Gritter H., Banerjee D.
EB-virus-induced common variable immunodeficiency disease. A case report.
Canadian Congress of Laboratory Medicine. Vancouver, June 19-23, 1982.

21 Banerjee D.
T lymphocytes in human intestinal mucosa: in situ demonstration of T-helper and T-suppressor subsets with monoclonal antibodies. Royal Coll. Phys. Surg. Canada, Annual Meeting, Quebec City, September 1982.

20 Banerjee D.
Morphologic and immunologic characteristics of immunoblastic sarcoma of T cell origin. Canadian Congress of Laboratory Medicine, Vancouver, June 19-23, 1982.

19. Banerjee D.
Localization of T lymphocyte subsets in human tonsillar tissue using monoclonal antibodies.
Comparison of immunofluorescence and immunoenzymatic systems.
Canadian Congress of Laboratory Medicine. Vancouver, June 19-23, 1982.

18. Banerjee D.
In vitro studies of peripheral blood mononuclear cells from patients with inflammatory bowel disease.
Canadian Congress of Laboratory Medicine, Vancouver, June 19-23, 1982.

17. Silver M.M., Banerjee D., Hudson A.J.
Segmental myofibre necrosis in myotonic dystrophy. 6th National Scientific Workshop of the Muscular Dystrophy Association of Canada. Banff, Alberta, February 5-7, 1932.

16. Banerjee D., McClintock J., Silver M.M., Hudson A.J.
Monocyte IgG Fc receptor concentration and affinity in myotonic dystrophy. 6th National Scientific Workshop of the Muscular Dystrophy

Association of Canada, Banff, Alberta, February 5-7. 1932.

15. Banerjee D., Richter M.
Naturally occurring cell-mediated cytotoxicity: an in vitro phenomenon distinct from the antibody- dependent cellular cytotoxic reaction. Lab. Invest. 46~S3.A, 1982.

14. Banerjee D., Silver M.M., McClintock J., Hudson A.J.
Abnormal shedding of monocyte $I_0C$ Fc receptors in myotonic dystrophy. Lab. Invest. 46:7.A, 1982.

13. Banerjee D.
Extramedullary myeloblastoma simulating non-Hodgkin's lymphoma. 8th International Congress of Lymphology, September 20-25, 1981, Montreal.

12. Banerjee D.
Metastatic carcinoma expressing monocyte-histiocyte cytochemical markers.
8th International Congress of Lymphology, September 20-25, 1931, Montreal.

11. Rush D.N., Clark W.F., Banerjee D., Keown P.A.
Fc-receptor mediated human monocyte chemiluminescence. Clin. Invest. Med. 4:2, 292, 1981.

10. Banerjee D.
Node-based T cell lymphoma: morphological diversity in three immunologically confirmed cases. International Conference on Malignant Lymphomas. September 2-5. 1081. Lugano, Switzerland.

9. Banerjee D.
Lymphoproliferative disorders - current concepts. 2nd National Congress. Q.S.L.T., June 21-26, 1981. London.

8. Wright B.A., Wysocki G.P., Banerjee D.
The diagnostic use of immunoperoxidase in plasma cell lesions in the jaw. First Scientific Meeting, International Association of Oral Pathologists. June 1-4,1981, Goteborg, Sweden.

7. Banerjee D.
Defective monocyte-mediated lysis in patients with mammary carcinoma and fibrocystic disease of breast. Can. Rev. Lab. Med. 3:17, 1981.

6. Banerjee D.
Dinitrochlorobenzene (DNCB) induced colitis in rabbits. Severe colitis related to cutaneous anergy to DNCB. IAP 70th Annual Meeting, March 2-6, 1Q81. Chicago. Illinois.

5. Banerjee D.
Distribution of macrophage-histiocytic muramidase activity in diffuse large-cell lymphomas. An immunohistochemical study. IAP 70th Annual Meeting, March 2-6, 1931, Chicago. Illinois.

4. Banerjee D.
Pulmonary eosinophilic granuloma in a patient with Hodgkin's disease. An ultrastructural study. Can. Rev. Lab. Med. 3:14,1981.

3. Banerjee D., Walley V. Anderson &
Non-Hodgkin's lymphoma terminating as lymphocyte depleted Hodgkin's disease. A morphological and immunoperoxidase study. Joint Meeting of the 18th Congress of the international Society of Hematology and the 16th Congress of the International Society of Blood Transfusion, Montreal, August 16-22,1980.

2. Walley V., Banerjee D., Gilbert J.J.
Metastasis or new primary? Immunoperoxidase as an aid. Can. Rev. Lab. Med., vol. 2,1980, pp 2.

1. Banerjee D., Ahmad D.
The clonal nature of B lymphocytes in lymphocytic interstitial pneumonia preceding non-Hodgkin's lymphoma. American Thoracic Society, 75th Annual Meeting, Washington, D.C., May 18-21. 1060.

**Chapters in Books:**

6. Lala PK, Al-Mutter N, Parhar RS, Sarloos MN, Banerjee D, Bramwell V. Mertens WC. Combination of chronic indomethacin and intermittent interleukin-2 therapy in the treatment of disseminated cancer. In: Combination Therapies 2, AL Goldstein, E Garaci (eds), New York, Plenum Press, 1993 pp 155-165.

5. Cherian MG., Panemangalore M., Banerjee D. The cellular accumulation and subcellular localization of metallothionein in rat liver during postnatal development. In Reproductive and Developmental Toxicity of Metals'. T.W. Clarkson. CF. Nordberg and P.R. Sager (eds.), Plenum Press, N.Y., 1983, pp 675-692.

4. Cherian MG., Banerjee D.
Immunohistochemical Localization of Metallothionein. In Methods in Enzymology; Academic Press. Methods in Enzymology, Vol. 205. Metallobiochemistry, Part B, Metallothionein and Related Molecules, pp 88-95, 1991, John N. Abelson and Melvin I. Simon. Editors.

3. Banerjee D., Baril J., Bell BA., McFarlane 0., Karim R.
Suppression of Immunoglobulin Production by Germinal Centre HNK-1+ CD34 Cells. In Histophysiology of the Immune System: The Life History, Organization and Interactions of Its Cell Population. Fossum and B. Rolstad; Plenum Press. Advances in Experimental Medicine and Biology, Vol. 237, pp 421-425, 1988.

2. Banerjee D.
Phenotypic and Functional Analyses of Tumour-Infiltrating Leu 7+ Natural Killer-Like Cells in Non-Hodgkin Lymphomas. Chapter - Immunobiology of Cancer and AIDS: Etiology, Diagnosis and Management. Herbert E. Nieburgs and J. George Bekesi, Editors, 1987.

| | |
|---|---|
| | 1. Richter M., Banerjee D., Fernando L., Sklar S. The Identity of the Naturally-Occurring Cytotoxic Cells in Man. H the Molecular Basis of Immune Cell Function. J. Gordin Kaplan, Editor, Elsevier/North-Holland Biomedical Press. 1979. |
| **AS A LEADER IN PLANNING, RE-ENGINEERING, RESTRUCTURING OF LARGE SCALE OPERATIONS**<br><br>15 YEARS EXPERIENCE | **2007**<br>Member, Best Practice & Innovation Team, PHSA imPROVE (LEAN) Program<br>**2004-2006**<br>Member, Steering Committee for Amalgamation of Clinical Laboratories at BC Cancer Agency, BC Children's Hospital, BC Women's Hospital, BC Centre for Disease Control, and Riverview Hospital.<br>**1996-2000**<br>Member, Pathology Committee Cancer Care Ontario<br>**1996**<br>Nucleus Committee on Surgical Oncology, Cancer Care Ontario, Member.<br>**1995**<br>Strategy Group, Provincial and Regional Cancer Planning, Cancer Care Ontario, Member<br>**1995**<br>Team Leader, Ambulatory Care Re-engineering and Re-structuring Team, Princess Margaret Hospital/Ontario Cancer Institute - $7 million annual savings achieved<br>**1994-95**<br>PMH Foundation Task Force. Member.<br>**1993-94**<br>Board Planning Committee, Princess Margaret Hospital/Ontario Cancer Institute, Member.<br>**1993-94**<br>Move Planning Committee, Princess Margaret Hospital/Ontario Cancer Institute, Member (planned move from Sherbourne Site to University Avenue). The entire hospital and clinical labs were moved over one weekend without interruption of services. |
| **AS AN INVENTOR**<br><br>3 PATENTS FILED | **Patents held:**<br><br>**1. Title:** Reagent Delivery Apparatus and Methods<br>**Patent Number:** PCT Application 04-116<br>**Date:** 6/9/2004 (file date)<br>**Countries of Issue:** PCT & US<br>**Name of the Inventors:** Diponkar Banerjee, Andrea Marziali, Kurtis Guggenheimer, Jared Slobodan, Roy Belak, David K Brown, Jason Thompson.<br>**Relevance or Impact (abstract/summary):**<br>FIELD OF INVENTION<br>A method of delivering minute quantities of individual antibodies or nucleic acid probes to tissue microarrays or cell arrays on glass slides without cross-contamination, with the ability to set slide temperatures for the appropriate labeling and hybridization protocols.<br>ABSTRACT OF THE DISCLOSURE<br>Current methods of immunohistochemistry or in-situ hybridization are designed |

to localize a single protein or gene on a single section of tissue per slide or array of multiple tissue cores on a slide. The invention allows for the detection of multiple proteins or genes simultaneously on tissue array slides or cell array slides. Such a device will allow the detection of multiple predictive or prognostic biomarkers in individual patient biopsies including fine needle aspirations on a single slide without cross contamination, and by reducing reagent volume, such assays can be done at very low cost.

**2. Title:** Method for isolation of human monoclonal antibodies from tumor infiltrating B lymphocytes in biopsy samples
**Patent Number:** US60/681,966
**Date:** 05/18/2005 (file date)
**Countries of Issue:** United States
**Name of the Inventors:** Diponkar Banerjee and Samuel Abraham
**Relevance or Impact (abstract/summary):**
FIELD OF THE INVENTION
A method for isolating antibodies from tumor infiltrating B lymphocytes within human tumors. Antibodies isolated from such lymphocytes have utility in cancer diagnostics and also for cancer immunotherapy.
ABSTRACT OF THE DISCLOSURE
The current invention enables the isolation of human monoclonal antibodies from lymphocytes within biopsies of human tumors. Lymphocytes infiltrating human tumors represent the immune system's response to the tumor. Antibodies isolated from such lymphocytes represent a source of antibodies useful for cancer diagnostics and cancer therapies. The current invention enables the labeling and isolation of such lymphocytes and the isolation of the genetic information encoding tumor-recognizing antibodies from such lymphocytes. Additionally the current invention provides methods for the determination of the sequence encoding such antibodies and methods for producing the proteins encoded by said sequence. Finally the current invention provides a method for identifying such antibodies that recognize cancer-specific epitopes in the tumor and related cancers.

**3. Title:** Monoclonal Antibodies for the treatment of Lymphoma
**Patent Number:** Applic No. 60/681,966
**Date: filing date** 05/18/2005
**Countries of Issue:** United States
**Name of the Inventors:** Diponkar Banerjee
**Relevance or Impact (abstract/summary):**
**FIELD OF THE INVENTION**
The inventors provide compositions and methods for the diagnosis, prognosis and treatment of Lymphoma.
**ABSTRACT OF THE DISCLOSURE**
A method of treating lymphoma in a subject comprises administering to a subject afflicted with Lymphoma an antibody in a therapeutically effective amount. Preferably the antibody is one of antibodies anti-R9.14, anti-R24.1, anti-R23.1, or anti-R26.8 or an antibody that binds to the epitopes R9.14, R24.1, R23.1, or R26.8.

| | |
|---|---|
| **AS A NATIONAL LEADER** | President, Canadian Association of Pathologists 2004-2006<br>Past President, Canadian Association of Pathologists 2006-2007 |

CURRICULUM VITAE

UPDATED 23-JUL-08

**AS A COMMITTEE MEMBER OR CHAIR**

30 YEARS EXPERIENCE

**2007-**
Member, Advisory Group, Pathologist Assistant Training Program Curriculum Development, UBC
**2003-2006**
UBC Program Evaluation Committee, member
**1995-97**
Data Quality Committee of the Canadian Council of Cancer Registries, Member and Consultant Pathologist
**1993-94**
Risk Management Committee, Princess Margaret Hospital/Ontario Cancer
**1993-95**
Quality & Resource Management Committee, Princess Margaret Hospital! Ontario Cancer Institute, Toronto, Member
**1993**
Research Credentials Committee, Department of Pathology, University of Toronto, Division of Experimental Pathology, Member.
**1993-1994**
Chairman, Medical Advisory Committee, Princess Margaret Hospital/Ontario Cancer Institute.
**1992-93**
Vice-Chairman. Medical Advisory Committee, Princess Margaret I-Hospital/ Ontario Cancer Institute.
**1992-93**
Chairman, Credentials Committee, Princess Margaret Hospital/Ontario Cancer [Institute.
**1992-93**
Clinical Trials Committee, Princess Margaret Hospital/Ontario Cancer Institute, Member.
**1992-95**
Promotions and Appointments Committee, Department of Pathology, University of Toronto. Member.
**1991-93**
Medical Quality Improvement Committee. Princess Margaret Hospital/Ontario Cancer Institute. Member.
**1991-93**
Residency Training Committee, University of Toronto. Member.
**1991-97**
Haematology/Transfusion Advisory Committee. Princess Margaret Hospital/Ontario Cancer Institute, Member.
**1991-97**
Executive Committee, Department of Pathology, University of Toronto. Member
**1991 -97**
Medical Advisory Committee, Princess Margaret Hospital/Ontario Cancer Institute. Member.
**1991-97**
Research Advisory Committee. Princess Margaret Hospital/Ontario Cancer Institute. Member.
**1991-97**
Planning & Resources Coordinating Committee. Princess Margaret Hospital/Ontario Cancer Institute, Member.
**1991-97**
Medical Staff Association, Princess Margaret Hospital/Ontario Cancer Institute. Member.

**1991-97**
Department Heads & Senior Staff Committee, Princess Margaret Hospital/Ontario Cancer Institute, Member.
**1991 -95**
Princess Margaret Hospital/Ontario Cancer Institute-Wellesley Hospital Shared Laboratory Services Management Committee, Member.
**1991-96**
Anatomic Pathology Computer System Implementation Committee. Princess Margaret Hospital/Ontario Cancer Institute, Member.
**1991-97**
Post-Graduate Medical Education Committee, Princess Margaret Hospital/Ontario Cancer Institute, Member.
**1990-91**
Chairman. Medical Advisory Committee, St. Joseph's Health Centre, London.
**1990-91**
Board of Directors, St. Joseph's Health Centre, London, Member.
**1990-91**
London Teaching Hospitals Council, Member.
**1990-91**
Fiscal Advisory Committee, St. Joseph's Health Centre, London, Member.
**1989-90**
Vice-Chairman, Medical Advisory Committee. St. Joseph's Health Centre, London.
**1988-89**
Second Vice-Chairman, Medical Advisory Committee, St. Joseph's Health Centre, London.
**1987-90**
Co-ordinator, Residents Research Day, UWO. London.
**1987-90**
Administrative Laboratory Committee. St. Joseph's Health Centre, London, Member.
**1987-89**
Property & Planning Committee. St. Joseph's Health Centre, London.
**1986-91**
Medical Advisory Committee, St. Joseph's Health Centre, London, Member.
**1986-91**
Anatomical Pathology Residency Training Committee. UWO. Member.
**1986-89**
Faculty of Medicine Admissions Committee, UWO, Member.
**1986-91**
Lawson Research Institute Operations Committee, Member.
**1984-86**
Medical Education Committee, University Hospital, London, Member.
**1983-88**
Graduate Education Committee. UWO, Member.
**1981-84**
Postgraduate Medical Education Committee, UWO. Member.
**1980-82**
Tissue Committee. University Hospital, London, Member.
**1979-82**
Laboratory Services, Program Advisory Committee, University Hospital, London, Member.
**1979-81**

Medical Technologists Training Program, University Hospital. London, Director.
**1978-81**
Appointment, Promotion and Tenure Committee, UWO, Member

## EDUCATION

**UNDERGRADUATE MEDICAL TRAINING:**
1966-1971: Makerere Medical School, Uganda, East Africa.

**POST GRADUATE MEDICAL EDUCATION:**
**1972-1973:**
University of Minnesota Department of Laboratory Medicine. Resident R1
**1973-1974:**
University of Ottawa Department of Laboratory Medicine. Resident R2, combined with graduate program (PhD level) in Immunology
**1974-1975:**
University of Ottawa Department of Laboratory Medicine. Resident R3, combined with graduate program (PhD level) in Immunology
**1975-1976**
University of Ottawa Department of Laboratory Medicine, Resident R4, combined with graduate program (PhD level) in Immunology

**DEGREES:**

| | |
|---|---|
| MBChB. | Makerere Medical School (Medicine & Surgery) 1971 |
| FRCP(C) | Royal College of Physicians of Canada (Anatomical Pathology) 1978 |
| PhD. | University of Ottawa (Immunology of Natural Killer Cells) 1984 |